Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped up before the market opened on Thursday . The stock had previously closed at $39.79, but opened at $41.90. Zealand Pharma A/S shares last traded at $41.50, with a volume of 600 shares trading hands.

Analysts Set New Price Targets

Several research analysts have commented on the stock. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Up 1.0%

The company has a market cap of $2.86 billion, a PE ratio of 2.94 and a beta of 0.75. The company has a fifty day moving average of $62.13 and a two-hundred day moving average of $70.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $19.69 million. As a group, analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.